SeaStar Medical Holding Co. (NASDAQ:ICU) Short Interest Update

SeaStar Medical Holding Co. (NASDAQ:ICU) was the target of a significant increase in short interest in February. As of February 28th, there was short interest totalling 357,600 shares, an increase of 18.8% from the February 13th total of 300,900 shares. Based on an average daily volume of 421,900 shares, the short-interest ratio is presently 0.8 days. Approximately 4.2% of the company’s stock are short sold.

Institutional Trading of SeaStar Medical

A hedge fund recently raised its stake in SeaStar Medical stock. Geode Capital Management LLC boosted its stake in SeaStar Medical Holding Co. (NASDAQ:ICU) by 14.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,430 shares of the company’s stock after acquiring an additional 5,618 shares during the period. Geode Capital Management LLC owned 1.02% of SeaStar Medical worth $88,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 1.69% of the company’s stock.

SeaStar Medical Stock Down 3.7 %

Shares of NASDAQ ICU traded down $0.08 during trading on Wednesday, reaching $2.10. 326,684 shares of the stock were exchanged, compared to its average volume of 246,339. The business’s 50-day moving average price is $1.83 and its 200 day moving average price is $2.75. SeaStar Medical has a twelve month low of $1.50 and a twelve month high of $22.00. The company has a market capitalization of $13.59 million, a price-to-earnings ratio of -0.18 and a beta of -0.97.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.